Answers are grounded in this paper and cite their sources.
Alternative lengthening of telomeres (ALT) is a telomerase‐independent mechanism of telomere maintenance driven by homologous recombination‐associated DNA synthesis. It is common in osteosarcoma, selected glioma subtypes, and pancreatic neuroendocrine tumors. Recent studies have defined important roles of replication stress, chromatin regulation, and the nuclear organization of telomeres in ALT initiation and maintenance, identifying several candidate therapeutic targets. Most therapeutic evidence comes from cellular and animal models, with clinical observations limited to individual patients. How to accurately identify ALT‐positive tumors and select appropriate patients has therefore become a key question in translating mechanistic findings into clinical applications. C‐circle assays, telomere fluorescence in situ hybridization (FISH), and detection of ALT‐associated promyelocytic leukemia (PML) bodies assess different telomeric nucleic acid and nuclear features. Selecting assays according to specimen characteristics can improve the reliability of ALT classification. This review examines the molecular mechanisms, phenotypic assessment, clinical associations, and therapeutic investigation of ALT, focusing on how tumor‐specific target dependencies and drug responses inform the evaluation of ALT for patient stratification and treatment selection.
No takes yet. Share an insight, caveat, or question.
Tong et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: